Skip to main content

TCR2 Therapeutics Inc.

TCRRDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001750019

TCR2 Therapeutics Inc. was delisted in 2023; its insiders filed their last Form 4 on Feb 14, 2024; 59 institutions reported holding it in 13F filings for Q1 2023, worth $31.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by TCR2 Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for TCR2 Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for TCR2 Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Tang Kevin C10% Owner0IndirectFeb 14, 20240
Tang Capital Partners LP10% Owner0IndirectFeb 14, 20240
Tang Capital Management LLC10% Owner0IndirectFeb 14, 20240
MPM BioImpact LLC10% Owner0Jun 5, 20230
UBS Oncology Impact Fund L.P.10% Owner0Jun 5, 20230
Oncology Impact Fund (Cayman) Management L.P.10% Owner0Jun 5, 20230
MPM SunStates Fund, L.P.10% Owner0IndirectJun 5, 20230
MPM SunStates GP Managing Member LLC10% Owner0IndirectJun 5, 20230
MPM Asset Management Investors SunStates Fund LLC10% Owner0IndirectJun 5, 20230
MPM SunStates Fund GP LLC10% Owner0IndirectJun 5, 20230
Evnin Luke10% Owner0IndirectJun 5, 20230
MPM Asset Management LLC10% Owner0IndirectJun 5, 20230
Foley Todd10% Owner0IndirectJun 5, 20230
MPM BioVentures 2014, L.P.10% Owner0IndirectJun 5, 20230
MPM BioVentures 2014 (B), L.P.10% Owner0IndirectJun 5, 20230
MPM Asset Management Investors BV2014 LLC10% Owner0IndirectJun 5, 20230
MPM BioVentures 2014 LLC10% Owner0IndirectJun 5, 20230
MPM BioVentures 2014 GP LLC10% Owner0IndirectJun 5, 20230
Gadicke AnsbertDirector, 10% Owner0IndirectJun 5, 20230
Allen Andrew RDirector–Jun 1, 20230
Webster Stephen WDirector–Jun 1, 20230
Gibson Neil WDirector–Jun 1, 20230
Menzel Garry EPresident and CEO0Jun 1, 20230
Sullivan EricChief Financial Officer–Jun 1, 20230
Tomasello ShawnDirector–Jun 1, 20230
Justice AngelaChief People Officer0Jun 1, 20230
Cardama Alfonso QuintasChief Medical Officer0Jun 1, 20230
Hoos AxelDirector–Jun 1, 20230
Harrison RosemaryChief Business & Strategy–Jun 1, 20230
Olagunju PeterChief Operating Officer0Jun 1, 20230
Hegde PritiDirector–Jun 1, 20230
Hofmeister RobertChief Scientific Officer–Dec 10, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 30, 2023 (view filing)8:02 PM ETMay 255 daysTang Kevin C and 2 others10% OwnerPPurchase+50.0K$1.72+$86.0K+1.2%4.39M after
May 24, 2023 (view filing)4:39 PM ETMay 222 daysEvnin Luke and 1 other10% OwnerSSale−70.2K$1.88−$131.9K−18.8%304.0K afterDuplicate filing
May 24, 2023 (view filing)May 222 daysGadicke AnsbertDirector, 10% OwnerSSale−70.2K$1.88−$131.9K−18.8%304.0K after
May 15, 2023 (view filing)5:12 PM ETMay 11-124 daysTang Kevin C and 2 others10% OwnerPPurchase+44.9K$1.95+$87.6K+1.0%4.34M after2 lots
May 10, 2023 (view filing)7:02 PM ETMay 8-102 daysTang Kevin C and 2 others10% OwnerPPurchase+84.0K$1.95+$163.8K+2.0%4.30M after3 lots
May 5, 2023 (view filing)6:52 PM ETMay 3-52 daysTang Kevin C and 2 others10% OwnerPPurchase+289.6K$1.89+$547.9K+7.4%4.22M after4 lots
Dec 13, 2022 (view filing)Dec 9-134 daysCardama Alfonso QuintasChief Medical OfficerSSale−13.8K$1.10−$15.1K−11.2%109.5K after3 lots
Dec 13, 2022 (view filing)Dec 9-134 daysOlagunju PeterChief Technical OfficerSSale−4.83K$1.10−$5.31K−16.7%24.1K after3 lots
Dec 13, 2022 (view filing)Dec 9-124 daysJustice AngelaChief People OfficerSSale−8.62K$1.10−$9.45K−15.0%48.7K after3 lots
Dec 13, 2022 (view filing)Dec 9-134 daysMenzel Garry EPresident and CEOSSale−31.9K$1.10−$35.0K−18.7%138.9K after3 lots
Dec 9, 2022 (view filing)Dec 7-82 daysCardama Alfonso QuintasChief Medical OfficerSSale−7.94K$1.27−$10.1K−6.1%123.3K after2 lots
Dec 9, 2022 (view filing)Dec 7-82 daysMenzel Garry EPresident and CEOSSale−18.4K$1.26−$23.3K−9.7%170.8K after2 lots
Dec 9, 2022 (view filing)Dec 7-82 daysJustice AngelaChief People OfficerSSale−4.97K$1.27−$6.31K−8.0%57.4K after2 lots
Dec 9, 2022 (view filing)Dec 7-82 daysOlagunju PeterChief Technical OfficerSSale−2.79K$1.26−$3.53K−8.8%28.9K after2 lots
Dec 7, 2022 (view filing)Dec 5-62 daysCardama Alfonso QuintasChief Medical OfficerSSale−7.46K$1.35−$10.1K−5.4%131.2K after2 lots
Dec 7, 2022 (view filing)Dec 5-62 daysOlagunju PeterChief Technical OfficerSSale−2.62K$1.35−$3.53K−7.6%31.7K after2 lots
Dec 7, 2022 (view filing)Dec 5-62 daysMenzel Garry EPresident and CEOSSale−23.4K$1.36−$31.8K−11.0%189.2K after2 lots
Dec 7, 2022 (view filing)Dec 5-62 daysJustice AngelaChief People OfficerSSale−4.66K$1.35−$6.29K−7.0%62.3K after2 lots
Dec 5, 2022 (view filing)Dec 23 daysCardama Alfonso QuintasChief Medical OfficerSSale−3.64K$1.39−$5.05K−2.6%138.7K after
Dec 5, 2022 (view filing)Dec 23 daysOlagunju PeterChief Technical OfficerSSale−1.27K$1.39−$1.77K−3.6%34.3K after
Dec 5, 2022 (view filing)Dec 23 daysMenzel Garry EPresident & CEOSSale−8.41K$1.39−$11.7K−3.8%212.7K after
Dec 5, 2022 (view filing)Dec 23 daysJustice AngelaChief People OfficerSSale−2.27K$1.39−$3.16K−3.3%67.0K after